Physician profile
Kevin Falk
NPI 1790097939
$7,163.85
in general payments reported to CMS, 2019-2025
28 companies · $1,708 in 2025
The $1,708 reported for 2025 was more than what 91% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $94.92 · 2021: $1,069 · 2022: $1,338 · 2023: $1,311 · 2024: $1,524 · 2025: $1,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,542.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,123.19 | 2021-2025 | |
| Janssen Biotech, INC. | $1,283.59 | 2021-2025 | Stelara, Tremfya, Simponi |
| Daiichi Sankyo INC. | $1,103.41 | 2020-2025 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $651.22 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $647.42 | 2020-2025 | Entyvio, Eohilia |
| Amgen INC. | $208.81 | 2022-2023 | Avsola, Amjevita |
| Nestle Healthcare Nutrition INC. | $174.23 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $168.33 | 2024-2025 | Voquezna |
| Allergan, INC. | $118.50 | 2019 | |
| Redhill Biopharma INC. | $97.35 | 2021-2022 | |
| Braintree Laboratories, INC. | $76.42 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $72.17 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $54.05 | 2025 | Zenpep |
| Celltrion USA INC. | $53.55 | 2025 | Vegzelma |
| Qol Medical, LLC | $39.46 | 2025 | Sucraid |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $32.58 | 2024-2025 | Ibsrela |
| Vivus LLC | $32.17 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.00 | 2023 | Cyltezo |
| Axonics, INC. | $30.06 | 2022 | |
| Ironwood Pharmaceuticals, INC | $28.19 | 2020 | |
| Ferring Pharmaceuticals INC. | $23.12 | 2021 | |
| Lilly USA, LLC | $22.65 | 2024 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $20.63 | 2025 | Dupixent |
| Medtronic, INC. | $18.63 | 2025 | Interstim |
| Merck Sharp & Dohme LLC | $18.38 | 2024 | Dificid |
| Pfizer INC. | $13.19 | 2021 | |
| Novo Nordisk INC | $12.09 | 2022 | |
| Janssen Pharmaceuticals, INC | $9.46 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Falk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.